Physician profile
Christopher Curtis Custer
NPI 1417392028
$4,018.25
in general payments reported to CMS, 2019-2025
30 companies · $1,014 in 2025
The $1,014 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $617 · 2020: $328 · 2021: $317 · 2022: $213 · 2023: $1,297 · 2024: $232 · 2025: $1,014.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,461 · Travel and Lodging: $1,082.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,461.38 |
| Travel and Lodging | $1,081.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spinal Simplicity, LLC | $1,083.29 | 2023 | Ha Minuteman G3-R |
| Abbott Laboratories | $418.30 | 2019-2024 | Proclaim |
| Collegium Pharmaceutical, INC. | $352.36 | 2019-2025 | Belbuca |
| Abbvie INC. | $351.67 | 2021-2025 | Ubrelvy, Qulipta, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.93 | 2019-2025 | Relistor |
| Boston Scientific Corporation | $222.59 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management |
| Scilex Pharmaceuticals INC. | $202.56 | 2019-2024 | Ztlido |
| Medtronic, INC. | $178.38 | 2021-2025 | Vanta Adaptivestim, Intellis Adaptivestim |
| Saluda Medical Americas, INC. | $145.70 | 2025 | Evoke |
| Daiichi Sankyo INC. | $119.87 | 2019 | |
| Vertos Medical, INC. | $93.09 | 2019-2021 | |
| Biodelivery Sciences International, INC. | $93.06 | 2019-2021 | |
| Pfizer INC. | $66.60 | 2019-2025 | |
| Globus Medical, INC. | $64.69 | 2025 | Senza |
| Mdd US Operations, LLC | $61.67 | 2019 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $46.41 | 2019 | |
| Nevro Corp. | $28.92 | 2019 | |
| Amgen INC. | $28.23 | 2019-2020 | |
| Biotronik Nro, INC. | $19.59 | 2025 | Prospera |
| Vertex Pharmaceuticals Incorporated | $18.74 | 2025 | |
| Foundation Fusion Solutions, LLC | $16.97 | 2025 | |
| Painteq LLC | $16.82 | 2024 | Painteq |
| Virtus Pharmaceuticals LLC | $15.34 | 2025 | Levorphanol Tartrate |
| Kaleo, INC. | $13.32 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.66 | 2019 | |
| Redhill Biopharma INC. | $12.12 | 2021 | |
| Lilly USA, LLC | $11.94 | 2019 | |
| Si-Bone, INC. | $11.27 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $10.26 | 2019 | |
| Spr Therapeutics, INC | $6.90 | 2024 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Custer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.